Introduction
Bone is continuously remodeled by osteoblasts and osteoclasts through the balanced functions of a new bone formation and the resorption of old bone, respectively. Osteoclasts, the only cells capable of resorbing bone, originate from the same bone marrow precursor cells within the monocyte/macrophage lineage that give rise to macrophages and dendritic cells. Although osteoclast activity is necessary for skeletal morphogenesis and remodeling, excessive bone resorption by these cells is often associated with bone and joint diseases, such as osteoporosis and rheumatoid arthritis.

Bone resorption by osteoclasts requires a unique cytoskeletal structure referred to as the “actin ring” or “sealing zone.” Actin rings are transient structures that form only when the osteoclast is juxtaposed onto the bone. As the osteoclast detaches from the bone surface to access a new site of skeletal degradation, this ring structure disappears. Thus, the organization of the actin cytoskeleton is essential for osteoclasts to resorb bone.

The non-receptor tyrosine kinase c-Src plays multiple roles in cytoskeletal regulation and cell migration. c-Src activation is associated with the reorganization of actin within specific adhesion structures. Although c-Src is ubiquitously expressed, the primary phenotype associated with the targeted disruption of c-Src mice is osteopetrosis, a condition caused by the failure to resorb bone. This phenotype results from defective osteoclasts that express high levels of c-Src.

The receptor for activated C-kinase 1 (RACK1) is a scaffolding protein receptor for activated C-kinase 1 (RACK1) mediates receptor activator of nuclear factor κB ligand (RANKL)-dependent activation of p38 MAPK in osteoclast precursors; however, the role of RACK1 in mature osteoclasts is unclear. The aim of our study was to identify the interaction between RACK1 and c-Src that is critical for osteoclast function. A RACK1 mutant protein (mutations of tyrosine 228 and 246 residues to phenylalanine; RACK1 Y228F/Y246F) did not interact with c-Src. The mutant retained its ability to differentiate into osteoclasts; however, the integrity of the RANKL-mediated cytoskeleton, bone resorption activity, and phosphorylation of c-Src was significantly decreased. Importantly, lysine 152 (K152) within the Src homology 2 domain of c-Src is involved in RACK1 binding. The c-Src K152R mutant (mutation of lysine 152 into arginine) impaired the resorption of bone by osteoclasts. These findings not only clarify the role of the RACK1-c-Src axis as a key regulator of osteoclast function but will also help to develop new antiresorption therapies to prevent bone loss-related diseases.
of G proteins. RACK1 was initially identified as a scaffold for protein kinase C (PKC) and as a multifunctional scaffolding protein. RACK1 interacts with PKC, c-Src, and phosphodiesterase isoform PDE4D5 as well as with the cytoplasmic domain of several membrane-bound receptors, including integrin β3, N-methyl-D-aspartate receptor, and insulin-like growth factor receptor I, thereby integrating the signals from various signal transduction pathways in osteoclasts by functioning as a scaffold that linked c-Src to various receptors, including RANK and αVβ3 integrin. Our findings provide insights into the mechanism by which RANK mediates cytoskeletal reorganization during the process of bone resorption.

**Materials and methods**

**Mice and cells**

Bone marrow-derived macrophages (BMMs) derived from 6–8-week-old male C57BL/6 mice (The Jackson Laboratory) were prepared as previously described. The 293T cell line was used for the protein–protein interaction experiments. All animal experiments were approved by the Institutional Animal Care and Use Committee of Ewha Laboratory Animal Genomics Center and were conducted in accordance with the approved guidelines.

**Plasmids**

The pcDNA3.1 vector encoding HA-RACK1 was provided by M.J.W. (University of Virginia Health System, Charlottesville, VA, USA). The empty pMX-puro vector, pMX-puro-WT-RACK1, pMX-puro-control shRNA, and pMX-puro-shRACK1 were described previously. Mutant constructs (RACK1 Y228F/Y246F and c-Src K152R) were generated using site-directed mutagenesis with QuikChange reagents (Stratagene, La Jolla, CA, USA). Recombinant retroviral vectors encoding RACK1 Y228F/Y246F, c-Src WT, and c-Src K152R were generated by subcloning the corresponding cDNAs into the retroviral pMX-puro vector.

**Reagents**

Recombinant human M-CSF was purchased from R&D Systems (Minneapolis, MN, USA). RANKL was obtained from Peprotech EC (London, England). The antibody against RACK1 used for western blotting was purchased from BD Biosciences (San Jose, CA, USA). Anti-c-Src was purchased from R&D Systems (Minneapolis, MN, USA). Anti-phospho-c-Src and anti-HA were purchased from Cell Signaling Technology (Beverly, MA, USA). The anti-RACK1 antibody used for immunoprecipitation, as well as anti-NFATc1, anti-4G10 and anti-β-actin, was obtained from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Anti-Atp6v0d2 was provided by Y.C. (University of Pennsylvania, Philadelphia, PA, USA).

**Transfection experiments and protein analysis**

Cells were transfected with expression vectors using PEI transfection reagent (Sigma-Aldrich). For the coexpression assays, 293T cells were transfected with the indicated expression vectors. The transfected cells were analyzed using western blotting. The cell lysates were immunoprecipitated with the indicated antibodies and subsequently analyzed using western blotting.

**Retrovirus preparation**

Retroviruses were prepared by transfecting PLAT-E packaging cells with empty pMX-puro vector, pMX-puro-WT-RACK1, pMX-puro-MT-RACK1, pMX-puro-control shRNA, or pMX-puro-shRACK1 using the PEI transfection reagent (Sigma-Aldrich). BMMs were infected with the retroviruses as previously described. The pMX-puro vector and PLAT-E cells were kindly provided by T.K. (University of Tokyo, Tokyo, Japan). After infection, the BMMs were cultured overnight, detached with trypsin/ethylenediaminetetraacetic acid, and further cultured in the presence of 30 ng/mL M-CSF and 2 μg/mL puromycin for 2 days. Puromycin-resistant BMMs were induced to differentiate by culturing the cells with 30 ng/mL M-CSF and 100 ng/mL RANKL for an additional 3–4 days.

**In vitro osteoclast differentiation**

The cells were fixed and stained for the presence of tartrate-resistant acid phosphatase (TRAP) using a TRAP staining Kit (Sigma-Aldrich). Osteoclast-like cells were defined as pink TRAP-positive multinucleated cells (i.e., more than three nuclei). The results of the osteoclast formation assays represent the mean of three independent experiments performed in triplicate ± standard deviation (SD) of the mean.

**Actin ring reformation**

Actin ring staining and quantitation were conducted as previously described. Briefly, mature osteoclasts were seeded on bone slices and cultured with 30 ng/mL M-CSF and 100 ng/mL RANKL for 2 days to induce the osteoclast phenotype. The actin rings were disrupted by washing the bone slices twice with cold cytokine-free medium, after which the slices were incubated in osteoclast differentiation medium for 120 min. The slices were fixed and stained with Alexa Fluor 488-phalloidin. The osteoclasts were identified using a Zeiss Axioplan II fluorescence microscope.
miceroscope (Zeiss). Osteoclasts were defined as cells containing at least three nuclei. The number of osteoclasts on each coverslip was noted, and a blinded investigator scored each osteoclast according to its type of actin cytoskeletal structure.

**Bone resorption assay**

Mature osteoclasts were seeded on bone slices and cultured with 30 ng/mL M-CSF and 100 ng/mL RANKL for 3 days. The bone slices were mechanically agitated to remove the cells and then stained with hematoxylin solution and Gill no. 3 for 10 min. Quantitative analysis of the resorbed pit area was conducted using ImageJ (NIH, Bethesda, MD, USA). Four bone slices were measured under each experimental condition.

**Real-time quantitative polymerase chain reaction**

BMMs were cultured with M-CSF in the presence or absence of RANKL for the indicated period of time. Total RNA was extracted using TRIzol (Invitrogen, Paisley, Scotland, UK) according to the manufacturer’s instructions. Total RNA was reverse transcribed into cDNA using an M-MLV Kit (SolGent, Seoul, Korea). Polymerase chain reaction (PCR) amplification was conducted using a SYBR Green Master Kit (Kapa Biosystems, Woburn, MA, USA). The ABI PRISM 7300 system (Applied Biosystems, Foster City, CA, USA) was used to amplify DNA and detect the resulting products. Each experiment was conducted in triplicate, and the expression levels of the target genes were normalized to those of actin. The melting curve was analyzed to ensure that only the desired PCR product was present. The gene-specific primers for real-time PCR were as follows: RACK1 sense, 5′-GCCTCTGGGATCTCACAAC-3′ and antisense, 5′-AAGTTTACCTGCTCCTGGGG-3′; Src sense, 5′-ACCACCTTCGGCGCCCTCTATG-3′ and antisense, 5′-GCCACCCAGTCCTCTATG-3′; NFATc1 sense, 5′-CCAGGAAATACATCGAGGGCC-3′ and antisense, 5′-GGTGGATGTGAACCTGGAGAAG-3′; Actin sense, 5′-AGATGGTGGATCAGAAGCAGC-3′ and antisense, 5′-GGCAGAAGCTTAGGGTTTGTCA-3′. Data were normalized to β-actin mRNA expression.

**Western blot analysis**

The cells were lysed in a buffer containing 20 mM HEPES (pH 7.0), 150 mM NaCl, 1% Triton X-100, 10% glycerol, proteinase inhibitors (1 mM PMSF and 1 μg/mL leupeptin and aprotinin) and phosphatase inhibitors (1 mM NaVO4 and 1 mM NaF) after vortexing on ice for 30 min. After centrifuging for 20 min, the supernatants were boiled in 6X SDS sample buffer containing 0.6 M DTT. Cell lysates or immunoprecipitated proteins were separated using 10% SDS-polyacrylamide gels and electrotransferred onto a PVDF membrane (Millipore, Billerica, MA, USA). The membranes were blocked with 5% bovine serum albumin in Tris-buffered saline containing 0.1% Tween-20 and were immunoblotted with primary antibodies against RACK1, c-Src, phospho-c-Src, 4G10 (1:1000), HA (1:2000), NFATc1 (1:500), β-actin (1:5000), and Atp6v0d2 (1:10000) and secondary antibodies conjugated to HRP (1:5000). Proteins were detected using an ECL detection Kit (Bio-Rad Laboratories, Hercules, CA, USA). Representative western blots and quantification (shown in the bar graph) of the indicated protein/control ratio in the cell lysates using ImageJ are shown in Figs. 1b, 2c, 3a–c and 4b.

**Protein–protein docking**

Three-dimensional structures of RACK1 (PDB id 4AOW) and the SH2 domain of c-Src (PDB ID 1FBZ) were obtained from the Protein Data Bank. Each protein structure was docked using the ZDOCK server and the web-based protein–protein docking simulator. During this modeling process, ZDOCK 3.0.2 was used for the protein complex. The top-scoring pose was selected from the predicted structures.

**Statistical analysis**

Data are expressed as the mean ± SD of at least three independent experiments. Statistical analyses were performed using Student’s t-test to analyze differences among the groups. *P < 0.01 and **P < 0.05 were considered statistically significant.

**Results**

**Expression of RACK1 during RANKL-induced osteoclastogenesis**

RACK1 is highly expressed in all mammalian cells at relatively constant levels; however, RANKL stimulation during osteoclast formation promoted a gradual increase in RACK1 expression at both the mRNA and protein levels (Fig. 1a, b). Consistent with previous reports, we found that NFATc1 was upregulated at both the mRNA and protein levels 1 day after RANKL stimulation. NFATc1 mRNA and protein levels were at their maximum 2 days after RANKL stimulation and then declined (Fig. 1a, b). The upregulation of NFATc1 expression was accompanied by the upregulation of c-Src and Atp6v0d2, two known downstream targets of NFATc1. NFATc1, c-Src, and Atp6v0d2 protein levels were undetectable in BMMs, the cells that give rise to osteoclasts, but their levels increased during osteoclast differentiation. The expression pattern of RACK1 during RANKL-induced osteoclast formation suggests that RACK1 plays a role in the signaling pathway that mediates osteoclast function.
Fig. 1 RACK1 is upregulated during RANKL-induced osteoclastogenesis. Bone marrow-derived macrophages (BMMs) were cultured with 30 ng/mL M-CSF and 100 ng/mL RANKL for the indicated period of time. a RACK1, c-Src, NFATc1, and V-ATPase d2 mRNA levels were analyzed using real-time PCR. Data are presented as the mean ± SD of three independent experiments. *P < 0.01, **P < 0.05. b RACK1, c-Src, NFATc1, and V-ATPase d2 protein levels in whole cell lysates were analyzed by western blotting with antibodies specific for the indicated proteins. The ratio of RACK1 to actin was quantified from three independent experiments. *P < 0.01, **P < 0.05

Fig. 2 RACK1 associates with c-Src in osteoclasts. a BMMs were incubated in the presence or absence of 100 ng/mL RANKL for 3 days. The cells were lysed, and endogenous RACK1 was immunoprecipitated using anti-RACK1. The immunoprecipitates were analyzed using western blotting with anti-RACK1 and anti-c-Src. b First, 293T cells were transfected with plasmids expressing HA-RACK1 or c-Src as indicated. RACK1 was immunoprecipitated using anti-HA, and the immunoprecipitates and cell lysates were analyzed using western blotting with the indicated antibodies. The levels of exogenously expressed HA-RACK1 and c-Src in the cell lysates (Input) were assessed using western blotting. c The 293T cells were transfected with the indicated expression vectors. RACK1 was immunoprecipitated from cell lysates using anti-HA. The precipitated complexes and cell lysates were analyzed using western blotting with antibodies specific for the indicated proteins. The ratio of 4G10 to HA-RACK1 was quantified in each of three independent experiments. *P < 0.01, **P < 0.05. Western blots in a–c are representative of three independent experiments.
RACK1 interacts with c-Src in osteoclasts

Previous studies have shown that the interaction between RACK1 and c-Src regulates the proliferation of cancer cells. To investigate the molecular link between RACK1 and c-Src in osteoclasts, we first examined whether these two proteins associate in this context. The results of an immunoprecipitation assay using an antibody against RACK1 demonstrated that endogenous RACK1 interacts with c-Src in osteoclasts (Fig. 2a), but because BMMs do not express c-Src, the two proteins do not coimmunoprecipitate. This interaction was further confirmed by the observation that ectopically expressed c-Src coimmunoprecipitates with RACK1 in 293T cells (Fig. 2b), but because BMMs do not express c-Src, the two proteins do not coimmunoprecipitate. This interaction was further confirmed by the observation that ectopically expressed c-Src coimmunoprecipitates with RACK1 in 293T cells (Fig. 2b). Consistent with a previous report, c-Src did not phosphorylate a RACK1 mutant protein in which both tyrosine residues at positions 228 and 246 were replaced with phenylalanine (Y228F/Y246F) (Fig. 2c). Furthermore, the RACK1 mutant protein did not bind to c-Src, which suggests that the interaction between c-Src and RACK1 is mediated by tyrosine phosphorylation on Y228 and/or Y246 (Fig. 2c).

Y228F/Y246F mutations in RACK1 do not influence RANKL-induced osteoclastogenesis

We previously demonstrated that RACK1 functions as a scaffolding protein in the p38 MAP kinase pathway, indicating the link between the RANKL signaling cascade and osteoclastogenesis. To investigate the effect of the RACK1 mutation (Y228F/Y246F) on RANKL-induced osteoclast formation, we overexpressed wild-type (WT) or mutant RACK1 in BMMs. The overexpression of either the WT or mutant RACK1 enhanced the formation of large multinucleated osteoclasts (Supplementary Fig. S1a, b). Moreover, NFATc1 levels in the cells that overexpressed mutant RACK1 were similar to those in cells expressing WT RACK1 (Supplementary Fig. S1c). These results suggest that the interaction between c-Src and RACK1 and the c-Src-mediated phosphorylation of RACK1 are not involved in osteoclast differentiation.

RACK1 regulates actin ring and pit formation through interaction with c-Src

Based on the observation that RACK1 and c-Src within osteoclasts interact, we hypothesized that RACK1 might...
regulate c-Src activity in these cells. Because c-Src plays an essential role in cytoskeletal organization by osteoclasts, we examined the effect of RACK1 overexpression on the formation of the actin ring, a cytoskeletal structure essential for optimal osteoclast-mediated bone resorption. To this end, we generated mature osteoclasts on dentin discs. As shown in Fig. 5a, the number of actin rings significantly increased in the RANKL-stimulated cells that overexpressed WT RACK1 compared with the control cells; however, RANKL-stimulated cells that overexpressed mutant RACK1 failed to promote actin ring formation. Consistent with these results, the bone resorption activity of the RACK1-overexpressing osteoclasts significantly increased compared with that in the control osteoclasts (Fig. 5b), whereas the bone resorption activity of osteoclasts overexpressing mutant RACK1 was markedly decreased compared with that in the control osteoclasts. These results suggest that the interaction between RACK1 and c-Src in osteoclasts is necessary for osteoclast-mediated actin ring formation and bone resorption.

**RACK1 mediates RANKL- and integrin-mediated c-Src phosphorylation**

To further elucidate the function of the interaction between RACK1 and c-Src in osteoclasts, we examined the effect of RACK1 on c-Src phosphorylation in cells stimulated with RANKL and integrin. The overexpression of WT RACK1, but not the overexpression of mutant RACK1, enhanced RANKL-induced c-Src phosphorylation (Fig. 3a). A similar result was observed in RACK1-knockdown osteoclasts (Fig. 3b). Because αVβ3 integrin-induced c-Src phosphorylation is a key step in actin ring formation, we investigated the effect of RACK1 on integrin-mediated c-Src phosphorylation. To this end, we plated osteoclasts on vitronectin-coated plates for 15 min to promote integrin clustering. c-Src phosphorylation levels significantly increased in cells overexpressing WT
RACK1 compared with control cells, whereas c-Src phosphorylation levels strongly decreased in cells overexpressing mutant RACK1 (Fig. 3c). Interestingly, neither WT nor mutant RACK1 affected M-CSF-induced c-Src phosphorylation (Supplementary Fig. S2a). Together, these results suggest that RACK1 promotes RANKL- and integrin-induced c-Src phosphorylation in osteoclasts.

The K152 residue of c-Src is involved in the RACK1 interaction

A computational protein–protein docking study predicted that RACK1 was bound to the SH2 domain of c-Src through specific hydrogen bonding between Y246 in RACK1 and the K152 residue in c-Src. Furthermore, K152 showed favorable van der Waals interactions with Y228 in RACK1 (Fig. 4a). To confirm that the K152 residue in c-Src is responsible for RACK1 binding, we mutated K152 into arginine (K152R) and tested its interaction with RACK1. The c-Src K152R mutant association with RACK1 was impaired, while that of WT c-Src was not (Fig. 4b). Importantly, the bone resorption activity of the c-Src K152R mutant in the osteoclasts significantly decreased compared with that in the WT c-Src (Fig. 4c). These observations suggest a model in which RACK1 interacts with K152 within the SH2 domain of c-Src. Furthermore, this interaction is necessary for the bone resorption activity of osteoclasts.

Discussion

Although the involvement of c-Src in the regulation of RANK signaling has been documented\(^{14,35,38}\), the precise regulatory mechanism of c-Src in this context has remained elusive. Previous studies have suggested that the regulation of c-Src in RANK relies on TRAF6\(^{39,40}\), a signaling adaptor common to the IL-1R/TLR family and TNFR superfamily;\(^{27,41,42}\) however, pathways independent of TRAF6 have also been implicated in this process\(^{43,44}\). The present study demonstrated that RACK1 plays a key role in RANK-mediated c-Src activation and that the phosphorylation of RACK1 by c-Src enhances...
RANKL-induced actin ring formation in osteoclasts. These findings represent a potential mechanism of the underlying activation of the RANK signaling cascade by the RACK1-c-Src axis. Our findings also provide insight into the mechanism underlying the crosstalk between c-Src and RACK1 in response to RANKL stimulation.

In osteoclasts, c-Src is essential in the regulation of membrane ruffling and the formation of actin rings that facilitate adhesion to the bony matrix and bone resorption. Similarly, multiple factors, including M-CSF, integrin, and RANKL, rapidly induce changes in cytoskeletal organization to promote cell spreading, cell motility, and actin ring formation. c-Src is a key component of the signaling pathways that regulate the osteoclast cytoskeleton in response to M-CSF, integrin, and RANKL, which suggests that these factors most likely regulate the osteoclast cytoskeleton through c-Src; however, the mechanism underlying c-Src regulation in response to specific stimuli in the osteoclasts remains unclear. We propose that the scaffolding protein RACK1 is a key component of the c-Src pathway in osteoclasts and that RACK1 links c-Src signaling to RANKL and integrin but not to M-CSF.

The recruitment and activation of c-Src into the RANK receptor most likely involves a multistep process. First, RANKL stimulation induces RANK oligomerization to recruit TRAF6. RACK1 is subsequently recruited to the receptor complex by TRAF6. RACK1 either directly recruits c-Src to the receptor complex, and/or TRAF6 activates c-Src and induces it to interact with other signaling molecules. In this context, RACK1 most likely functions as an important regulator that selectively recruits signaling modules to c-Src in response to specific stimuli. The scaffolding function of RACK1 is reminiscent of the role of β-arrestin 1 in recruiting c-Src to the β2 adrenergic receptor, a G protein-coupled receptor. Receptors that lack intrinsic tyrosine kinase activity might need adaptor or scaffolding proteins, such as TRAF6 and RACK1, to recruit and activate Src family kinases.

The expression pattern of RACK1 during osteoclast formation and osteoclast-mediated bone resorption supports the hypothesis that RACK1 participates in the signaling pathways that mediate these processes. Multiple studies have demonstrated that the association between RACK1 and β1/β2 integrin and between RACK1 and c-Src regulates cell adhesion and cell motility in cancer cells. Notably, because osteoclast adhesion and spreading play important roles in bone resorption, the role of RACK1 in these processes merits further investigation.

In conclusion, we propose that RACK1 functions as a scaffolding protein in the c-Src pathway, thereby linking it to the RANKL-signaling cascade. c-Src phosphorylates RACK1 on Tyr 228 and/or Tyr 246. Tyr 228 and Tyr 246 are highly conserved residues located in the sixth tryptophan-aspartic acid repeat, which in turn interacts with the SH2 domain of c-Src. We speculate that RACK1 is an important c-Src substrate that transduces signals downstream of RANK and is involved in the regulation of c-Src activation and osteoclast cytoskeletal reorganization.
12. Alper, O. & Bowden, E. T. Novel insights into c-Src. *Curr. Pharm. Des.* **11**, 1119–1130 (2005).
13. Destaing, O. et al. The tyrosine kinase activity of c-Src regulates actin dynamics and organization of podosomes in osteoclasts. *Mol. Biol. Cell* **19**, 394–404 (2008).
14. Soriano, P., Montgomery, C., Geske, R. & Bradley, A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. *Cell* **64**, 693–702 (1991).
15. Horne, W. C. et al. Osteoclasts express high levels of pp60-src in association with intracellular membranes. *J. Cell Biol.* **119**, 1003–1013 (1992).
16. Lowell, C. A. & Soriano, P. Knockouts of Src-family kinases: stiff bones, wimpy T cells, and bad memories. *Genes Dev.* **10**, 1845–1857 (1996).
17. McCaffill, A., Warwicker, J., Bolger, G. B., Houslay, M. D. & Yarwood, S. J. The RACK1 scaffold protein: a dynamic cog in cell response mechanisms. *Mol. Pharm.* **62**, 1261–1273 (2002).
18. Ron, D. et al. Cloning of an intracellular receptor for protein kinase C: a homolog of the beta subunit of G proteins. *Proc. Natl Acad. Sci. USA* **91**, 839–843 (1994).
19. Mamidipudi, V. & Cartwright, C. A. A novel pro-apoptotic function of RACK1: suppression of Src activity in the intrinsic and Akt pathways. *Oncogene* **28**, 4421–4433 (2009).
20. Bird, R. J., Baillie, G. S. & Yarwood, S. J. Interaction with receptor for activated C-kinase 1 (RACK1) sensitizes the phosphodiesterase PDE4D5 towards hydrolysis of cAMP and activation by protein kinase C. *Biochem. J.* **432**, 207–216 (2010).
21. Besson, A., Wilson, T. L. & Yong, V. W. The anchoring protein RACK1 links protein kinase Cip2 in osteoclasts. *Bone Cells*. (2011).
22. Wang, J. et al. Long-lasting adaptations of the NRG5-containing NMDA receptors in the dorsomedial striatum play a crucial role in alcohol consumption and relapse. *J. Neurosci.* **30**, 10187–10198 (2010).
23. Keily, P. A., Sant, A. & O'Connor, R. RACK1 is an insulin-like growth factor 1 (IGF-1) receptor-interacting protein that can regulate IGF-1-mediated Akt activation. *Oncogene* **28**, 4421–4433 (2009).
24. Adams, D. R., Ron, D. & Keily, P. A. RACK1, a multifunctional scaffolding protein: Structure and function. *Cell Commun. Signal.* **9**, 22 (2011).
25. Lin, J., Lee, D., Choi, Y. & Lee, S. Y. The scaffold protein RACK1 mediates the RANKL-dependent activation of pp60c-src in osteoclast precursors. *Biochem J.* **8**, ra54 (2011).
26. Jang, D. H. et al. Inactivation of glycogen synthase kinase-3beta is required for osteoclast differentiation. *J. Biol. Chem.* **286**, 39043–39050 (2011).
27. Ko, R., Park, J. H., Ha, H., Choi, Y. & Lee, S. Y. Glycogen synthase kinase-3beta ubiquitination by TRAF6 regulates TLR3-mediated pro-inflammatory cytokine production. *Nat. Commun.* **6**, 6765 (2015).
28. Pierce, B. G. et al. ZDOCK server: interactive docking prediction of protein-protein complexes and symmetric multimers. *Bioinformatics* **30**, 1771–1773 (2014).
29. Robles, M. S., Boyault, C., Knutti, D., Padmanabhan, K. & Weitz, C. J. Identification of RACK1 and protein kinase Calpha as integral components of the mammalian circadian clock. *Science* **327**, 463–466 (2010).
30. Choi, H. K. et al. Early estrogen-induced gene 1, a novel RANK signaling component, is essential for osteoclastogenesis. *Cell Res.* **23**, 524–536 (2013).
31. Kim, K., Lee, S. H., Ha Kim, J., Choi, Y. & Kim, N. NFATc1 induces osteoclast fusion via up-regulation of Atpp60xd2 and the dendritic cell-specific transmembrane protein (DC-STAMP). *Mol. Endocrinol.* **22**, 176–185 (2008).
32. Song, I. et al. Regulatory mechanism of NFATc1 in RANKL-induced osteoclast activation. *FEBS Lett.* **583**, 2435–2440 (2009).
33. Mamidipudi, V. et al. RACK1 inhibits colonic cell growth by regulating Src activity at cell cycle checkpoints. *Oncogene* **26**, 2914–2924 (2007).
34. Chang, B. Y., Harte, R. A. & Cartwright, C. A. RACK1: a novel substrate for the Src protein-tyrosine kinase. *Oncogene* **21**, 7619–7629 (2002).
35. Miyazaki, T. et al. Src kinase activity is essential for osteoclast function. *J. Biol. Chem.* **279**, 17660–17666 (2004).
36. Lakalikoppi, P. T. & Vaanannen, H. K. Kinetics of the osteoclast cytoskeleton during the resorption cycle in vitro. *J. Bone Miner. Res.* **6**, 817–826 (1991).
37. Lakalikoppi, P. T. & Vaanannen, H. K. Cytoskeletal changes in osteoclasts during the resorption cycle. *Microsc. Res. Tech.* **33**, 171–181 (1996).
38. Zou, W. et al. Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. *J. Cell Biol.* **176**, 877–888 (2007).
39. Wang, B. R. et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. *Mol. Cell* **4**, 1041–1049 (1999).
40. Armstrong, A. P. et al. A RANK/TRA6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. *J. Biol. Chem.* **277**, 44347–44356 (2002).
41. Kim, J. M. et al. Induction of proinflammatory mediators requires activation of the TRAF, NIK, IKK, and NF-kappaB signaling pathway in astrocytes infected with Escherichia coli. *Clin. Exp. Immunol.* **140**, 450–460 (2005).
42. Kobayashi, T., Walsh, M. C. & Choi, Y. The role of TRAF6 in signal transduction and the immune response. *Microbes Infect.* **6**, 1333–1338 (2004).
43. Kim, H. et al. Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice. *J. Clin. Investig.* **119**, 813–825 (2009).
44. Iwama, T. et al. c-Src links a RANKalpha/beta3 integrin complex to the osteoclast cytoskeleton. *Mol. Cell Biol.* **32**, 2943–2953 (2012).
45. Boyce, B. F., Yoneda, T., Lowes, C., Soriano, P. & Mundy, G. R. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. *J. Clin. Investig.* **90**, 1622–1627 (1992).
46. Schwartzberg, P. L. et al. Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/- mutant mice. *Genes Dev.* **11**, 2893–2844 (1997).
47. Fuller, K., Wong, B., Fox, S., Choi, Y. & Chambers, T. J. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. *J. Exp. Med.* **188**, 997–1001 (1998).
48. Burgess, T. L. et al. The ligand for osteoprotegerin (OPLG) directly activates mature osteoclasts. *J. Cell Biol.* **145**, 527–538 (1999).
49. Satoh, S. et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. *Nat. Immunol.* **6**, 1087–1095 (2005).
50. Shim, J. H. et al. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. *Genes Dev.* **19**, 2668–2681 (2005).
51. Luttrel, L. M. et al. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. *Science* **283**, 655–661 (1999).
52. Boyle, W. J., Simonet, W. S. & Lacey, D. L. Osteoclast differentiation and activation. *Nature* **423**, 337–342 (2003).